Comparative Pharmacology

Head-to-head clinical analysis: CHLOROMYXIN versus NITROFURANTOIN.

Peer-Reviewed Evidence

Differential Analysis

CHLOROMYXIN vs NITROFURANTOIN

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

CHLOROMYXIN

Antibiotic

Category C

NITROFURANTOIN

Antibiotic

Category D/X

Head-to-Head

Clinical Matrix

Mechanism of Action

Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.

Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or inhibit bacterial ribosomal proteins, DNA, RNA, and metabolic enzymes, leading to bacterial cell death.

Clinical Dosing

500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.

100 mg orally twice daily for 5-7 days (uncomplicated UTI); 50-100 mg orally four times daily for 7 days (symptomatic uncomplicated UTI). Extended-release: 100 mg orally twice daily for 7 days.

Direct Interaction

None Documented

Other Significant Interactions

Clinical Note

moderate

Nitrofurantoin + Norfloxacin

"The therapeutic efficacy of Norfloxacin can be decreased when used in combination with Nitrofurantoin."

Clinical Note

moderate

Nitrofurantoin + Teriflunomide

"The serum concentration of Teriflunomide can be increased when it is combined with Nitrofurantoin."

Clinical Note

moderate

Nitrofurantoin + Probenecid

"The serum concentration of Probenecid can be increased when it is combined with Nitrofurantoin."

Clinical Note

moderate

Nitrofurantoin + Rolapitant